13:09:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 Årsstämma 2024
2024-03-13 Bokslutskommuniké 2023
2023-11-22 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Årsstämma 2022
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2023-01-10 09:57:49

Oslo, 10 January 2023 - Observe Medical ASA ("the Company" or "Observe Medical") announces it has appointed Jørgen Mann as the Company's Chief Commercial Officer. With nearly 20 years of experience in sales and senior management roles from global medtech companies in Europe, he brings highly relevant experience to Observe Medical, as the company strengthens its commercial efforts in the market.

Observe Medical recently announced it had signed agreements to acquire the Unometer portfolio of urine measurement products from Convatec, and a separate agreement to acquire Ferrari L., an Italian-based manufacturer of medical products. The agreement with Convatec also opens up sales channels in more than 50 countries for the urine measurement product portfolio, including Sippi®. In addition, Observe Medical's partnership with Fresenius Kidney Care in the US is progressiong well, and the Company is in the process of rolling out its Biim Ultrasound device to clinics nationwide.

"I am excited to welcome Jørgen to the Observe Medical team as our new Chief Commercial Officer. We are rapidly broadening our position and reaching into new markets, and I am confident he is the right person for this important role. He brings significant experience and know-how to Observe and will play a key role in leading our global commercial efforts alongside our growing portfolio of products," said Rune Nystad, CEO of Observe Medical.

Jørgen Mann joins Observe Medical from Fresenius Medical Care, where he was the Head of Country in Denmark from 2019. Before Fresenius Medical Care, he held regional and commercial roles at Smith&Nephew, a global medical technology company, and senior commercial positions at Arjo Huntleigh, which is part of the Getinge Group. He also worked at the Danish medtech firm Unomedical, which became part of Convatec in 2008.

Jørgen Mann has an Executive MBA from the Henley Management Institute and a Bachelor of Science from Helsingør Technical University, underpinned by continuous competence development within General Management, Leadership and Commercial Excellence.

For further information, please contact:
Rune Nystad, CEO Observe Medical

Mobile: +47 916 24 683

E-mail: rune.nystad@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A. The Company is headquartered in Oslo, Norway, Gothenburg (Sweden), Oulu (Finland), and Seattle (the US). In addition, Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.

Further information is available at www.observemedical.com.